Novel Rejuvenated T Cell Immunotherapy for Lung Cancer

Return to Grants

Grant Award Details

Grant Type:
Quest – Discovery Stage Research Projects
Grant Number:
DISC2-08874
Investigator(s):
Name:
Professor Hiromitsu Nakauchi
Institution:
Stanford University
Type:
PI

Disease Focus:
Cancer, Lung Cancer, Solid Tumors
Human Stem Cell Use:
iPS Cell
Cell Line Generation:
iPS Cell
Award Value:
$1,968,456
Status:
Closed

Progress Reports

Reporting Period:
Year 2

Grant Application Details

Application Title:

Novel Rejuvenated T Cell Immunotherapy for Lung Cancer

Public Abstract:
Research Objective

Through this project, we would like to evaluate how this T-iPSC-based immunotherapy that we have developed can eliminate lung cancer cells effectively in vivo using xenografted SCID mice.

Impact

This novel T-iPSC-based immunotherapy will provide another effective treatment for lung cancer and possible other malignancies by supplying unlimited number of young and active CTLs.

Major Proposed Activities

  • Peptides synthesis for EGFR mutation hot spots and selection of the peptides with affinity binding assay
  • Patient lung cancer/ blood cell culture and xenograft establishment in SCID mice for establishing tumor model
  • Peptide responsive T cell selection, IPS induction and T cell redifferentiation and expansion (rejCTL) for cell-based immunotherapy
  • transfusion of patient specific rejCTL cells into lung cancer grafted mice to treat tumors
  • Evaluation of the efficacy of rejCTL cell therapy by observing tumor sizes in xenografted mice
  • Statistical analysis and conclusion for this novel cell-based cancer treatment and contact FDA for initiation of a clinical trial
Statement of Benefit to California:
Lung cancer is known to cause the highest fatality rate. California State and citizens suffer similarly as the US and worldwide do. A fairly common HLA allele, e.g. HLA A0201 presents in up to 50% of California populations. Thus, we can provide an ‘off the shelf’ therapy for most of cancer patients. As a California based institute, we will succeed this research and pioneer this frontier cell- based immunotherapy, and conduct a possible clinical trial through CIRM funding.

Publications